Trevi therapeutics, inc. (TRVI)
CashFlow / Yearly
Dec'19Dec'18
Operating activities
Net loss

-26,050

-20,545

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

39

23

Changes in fair value of Series C redeemable convertible preferred stock liability

-

2,105

Changes in fair value of obligation for loan success fee

215

138

Accretion/accrual of term loan discounts and debt issuance costs

-

60

Stock-based compensation

1,127

496

Changes in operating assets and liabilities:
Receivables

374

135

Prepaid expenses

243

1,345

Accounts payable

777

66

Accrued expenses

1,416

772

Security deposit

-

33

Deferred lease obligation

-

-43

Net cash used in operating activities

-23,093

-18,289

Investing activities
Acquisitions of property, equipment and leasehold improvements

9

158

Net cash used in investing activities

-9

-158

Financing activities
Repayments of term loan

-

4,813

Payment of final fees on term loan

-

533

Payment of loan success fee

675

-

Proceeds from exercises of stock options

38

13

Proceeds from sale of Series C redeemable convertible preferred stock, net of issuance costs

9,963

10,496

Proceeds from issuance of common shares upon completion of initial public offering, net of underwriting commissions and discounts

51,150

-

Payments of initial public offering costs

1,213

1,534

Proceeds from private placement, net of private placement agent fees

13,950

-

Net cash provided by financing activities

73,213

3,629

Net cash increase (decrease)

50,111

-14,818

Supplemental disclosure of cash flow information
Interest paid

-

152

State research tax credits exchanged for cash

124

35

Supplemental disclosure of non-cash financing activities
Dividends accrued on redeemable convertible preferred stock

2,239

5,402

Series C redeemable convertible preferred stock liability reclassified to Series C Preferred Stock

-

1,009

Accretion on redeemable convertible preferred stock

-1,535

-370